ARAV

Aravive, Inc. Common Stock

Delisted

ARAV was delisted on the 26th of January, 2024.

 

About: Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Employees: 23

Financial journalist opinion

Charts implemented using Lightweight Charts™